Anticipating risk for human subjects participating in clinical research: Application of failure mode and effects analysis

Cancer Investigation

Volumn 24, Issue 2, 2006, Pages 209-214

  Cody, Robert J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Clinical research; FMEA; Human subjects protection

Indexed keywords

ACCURACY; BONE MARROW TRANSPLANTATION; CALCULATION; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; HUMAN; INSTITUTIONAL REVIEW; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROTECTION; RESEARCH SUBJECT; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; TREATMENT FAILURE;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; HUMANS; RESEARCH SUBJECTS; RISK MANAGEMENT;

EID: 33645010413     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500524678     Document Type: Review

References (12)

1. Kranz, G. Failure is not an option. Simon & Shuster, New York, 2000, 12.
2. Wiesel, E. Without conscious. N. Engl J. Med. 2005, 352, 1511-1513.
3. Faden, R.R.; Lederer, S.E.; Moreno, J.D. US medical researchers, the Nuremberg doctors trial, and the Nuremberg code. A review of findings of the Advisory Committee on Human Radiation Experiments. JAMA 1996, 276, 1667-1671.
4. Kaufman, J.L.; Pelligra, R.; Reingold, A.L.; Sackett, D.L.; Shapiro, H.T.; Mestin, E.M.; Woodward, B. Protection for human subjects in medical research. JAMA 2000, 283, 2387-2390.
5. Shalala, D. Protecting human subjects - what must be done. N. Eng. J. Med. 2000, 343, 808-810.
6. Angell, M. Investigators responsibilities for human subjects in developing countries. N. Engl. J. Med. 2000, 342, 967-969.
7. Moreno, J.; Caplan, A.L.; Wolpe, P.R. Updating protections for human subjects involved in research. JAMA 1998, 280, 1951-1958.
8. Stamatis, D.H. Failure mode effect analysis: FMEA from theory to execution. American Society for Quality, Quality Press, Milwaukee, WI, 2003.
9. McDermott, R.E.; Mikulak, R.J.; Beauregard, M.R. The basics of FMEA. Productivity, Inc. Portland, OR, 1996.
10. Roberts, R.G., Jr; Goulart, B.H.; Squitieri, L.; Stallings, S.C.; et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004, 292, 2130-2140.
11. Shah, S.; Whittle, A.; Wilfond, B.; Gensler, G.; Wendler, D. How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA 2004, 291, 476-482.
12. Christian, M.C.; Goldberg, J.L.; Killen, J.; Abrams, J.S.; et al. A central institutional review board for multi-institutional trials. N. Engl. J. Med. 2002, 346, 1405-1408.